Further, there was a notable contrast between the global differences seen for total CD4 + T cells (a lower proportion of Th17.1 cells in At-risk and Early RA than in anti-CCP3(−) Controls) and the differences seen for cit-CILP (a higher proportion of Th17.1 cells in at-risk) and cit-Agg (a higher proportion of Th17.1 cells Early RA than in anti-CCP3(−) Controls). This evidence concerns the gene CD4 and rheumatoid arthritis.